JenaValve recalls certain TAVR delivery catheters

Cardiovascularbusiness reports that JenaValve has initiated a Class II recall involving certain TAVR delivery catheters. The action concerns delivery catheters used with the Trilogy Transcatheter Heart Valve System.

Recall tied to deployment concerns

According to Cardiovascularbusiness, the recall was initiated because of a risk that clinicians could encounter issues when deploying the Trilogy Transcatheter Heart Valve System. The publisher describes the action as a Class II recall and identifies certain TAVR delivery catheters as the recalled products.

The supplied report frames the event around safety concerns associated with deployment of the Trilogy system. It does not provide further details on the nature of the issues clinicians may encounter during deployment.

Focus on the delivery catheter

The reported recall centers on certain delivery catheters rather than a broader conclusion about TAVR procedures. Cardiovascularbusiness links the recalled catheters to the Trilogy Transcatheter Heart Valve System and to the reported deployment concern.

For medical device sales professionals who support structural heart accounts, the event underscores the need for product discussions to remain specific to the reported recall. Communications should distinguish the delivery catheter component identified in the report from other products or procedure-related considerations not addressed in the supplied information.

Reported information remains limited

Cardiovascularbusiness reports the recall classification, the affected product category, and the stated reason for the action. The supplied report does not identify the scope of affected catheters, provide additional detail about the deployment issues, or describe further recall actions.

Sales professionals discussing the event can keep conversations grounded in the published facts: JenaValve initiated a Class II recall of certain TAVR delivery catheters after identifying a risk that clinicians may encounter issues when deploying the Trilogy Transcatheter Heart Valve System. Any discussion beyond those points is not supported by the supplied report.

Why the event matters for account conversations

The recall places attention on the delivery process for the Trilogy system. For teams working with clinical stakeholders in structural heart, the reported action is a reminder that safety communications should be handled with precision and tied to the specific product information available.

Cardiovascularbusiness attributes the recall to safety concerns involving potential clinician issues during deployment. The publisher’s report provides the basis for the event: certain JenaValve TAVR delivery catheters are subject to a Class II recall connected to use with the Trilogy Transcatheter Heart Valve System.